Paul S. Aisen

This study is testing whether a vaccine called AADvac1 can slow the progression of Alzheimer's disease in its earliest stages. It will involve 375 adults aged 50-80 who have very early signs of the disease. The vaccine targets a protein called tau, and researchers will see if it …

This clinical trial aims to test whether new drugs that target tau protein in the brain can slow Alzheimer's disease progression, either alone or combined with existing amyloid-targeting treatments. It will enroll 750 adults aged 50-80 who have early signs of Alzheimer's but mini…